Improved survival with MEK inhibition in BRAF-mutated melanoma
About 160,000 new cases of melanoma are diagnosed and 48,000 melanoma-related deaths occur worldwide each year.1 Among cancers in patients under 40 years of age, the incidence of melanoma is second only to that of breast cancer for women and leukemia for men.2 Before 2010, no systemic therapy had be...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
June 4, 2012
|
| In: |
The New England journal of medicine
Year: 2012, Jahrgang: 367, Heft: 2, Pages: 107-114 |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMoa1203421 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1056/NEJMoa1203421
|
| Verfasserangaben: | Keith T. Flaherty, M.D., Caroline Robert, M.D., Ph.D., Peter Hersey, M.D., Ph.D., Paul Nathan, M.D., Ph.D., Claus Garbe, M.D., Mohammed Milhem, M.B., Lev V. Demidov, M.D., Jessica C. Hassel, M.D., Piotr Rutkowski,M.D., Peter Mohr, M.D., Reinhard Dummer, M.D., Uwe Trefzer, M.D., James M.G. Larkin, M.D., Jochen Utikal, M.D., Brigitte Dreno, M.D., Marta Nyakas, M.D., Mark R. Middleton, Ph.D., Jürgen C. Becker, M.D., Ph.D., Michelle Casey, Ph.D., Laurie J. Sherman, R.N., Frank S. Wu, M.D., Ph.D., Daniele Ouellet, Ph.D., Anne-Marie Martin, Ph.D., Kiran Patel, Ph.D., and Dirk Schadendorf M.D., for the METRIC Study Group* |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1581114109 | ||
| 003 | DE-627 | ||
| 005 | 20220815013639.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180919s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa1203421 |2 doi | |
| 035 | |a (DE-627)1581114109 | ||
| 035 | |a (DE-576)511114109 | ||
| 035 | |a (DE-599)BSZ511114109 | ||
| 035 | |a (OCoLC)1341018834 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Flaherty, Keith T. |e VerfasserIn |0 (DE-588)1167357418 |0 (DE-627)1031024298 |0 (DE-576)511117086 |4 aut | |
| 245 | 1 | 0 | |a Improved survival with MEK inhibition in BRAF-mutated melanoma |c Keith T. Flaherty, M.D., Caroline Robert, M.D., Ph.D., Peter Hersey, M.D., Ph.D., Paul Nathan, M.D., Ph.D., Claus Garbe, M.D., Mohammed Milhem, M.B., Lev V. Demidov, M.D., Jessica C. Hassel, M.D., Piotr Rutkowski,M.D., Peter Mohr, M.D., Reinhard Dummer, M.D., Uwe Trefzer, M.D., James M.G. Larkin, M.D., Jochen Utikal, M.D., Brigitte Dreno, M.D., Marta Nyakas, M.D., Mark R. Middleton, Ph.D., Jürgen C. Becker, M.D., Ph.D., Michelle Casey, Ph.D., Laurie J. Sherman, R.N., Frank S. Wu, M.D., Ph.D., Daniele Ouellet, Ph.D., Anne-Marie Martin, Ph.D., Kiran Patel, Ph.D., and Dirk Schadendorf M.D., for the METRIC Study Group* |
| 264 | 1 | |c June 4, 2012 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 21.08.2019 | ||
| 520 | |a About 160,000 new cases of melanoma are diagnosed and 48,000 melanoma-related deaths occur worldwide each year.1 Among cancers in patients under 40 years of age, the incidence of melanoma is second only to that of breast cancer for women and leukemia for men.2 Before 2010, no systemic therapy had been shown to improve overall survival among patients with metastatic melanoma, and only modest improvements were observed with interferon as an adjuvant drug.3 Ipilimumab, a monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and vemurafenib, a selective BRAF inhibitor, have both been shown to improve survival among patients with metastatic melanoma . . . | ||
| 700 | 1 | |a Hassel, Jessica C. |d 1975- |e VerfasserIn |0 (DE-588)129790702 |0 (DE-627)480399069 |0 (DE-576)29783715X |4 aut | |
| 700 | 1 | |a Utikal, Jochen |d 1974- |e VerfasserIn |0 (DE-588)1026463750 |0 (DE-627)726765015 |0 (DE-576)371816580 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d Waltham, Mass. : MMS, 1928 |g 367(2012), 2, Seite 107-114 |h Online-Ressource |w (DE-627)266889484 |w (DE-600)1468837-2 |w (DE-576)075962454 |x 1533-4406 |7 nnas |a Improved survival with MEK inhibition in BRAF-mutated melanoma |
| 773 | 1 | 8 | |g volume:367 |g year:2012 |g number:2 |g pages:107-114 |g extent:8 |a Improved survival with MEK inhibition in BRAF-mutated melanoma |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa1203421 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180919 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 1026463750 |a Utikal, Jochen |m 1026463750:Utikal, Jochen |d 60000 |e 60000PU1026463750 |k 0/60000/ |p 14 | ||
| 998 | |g 129790702 |a Hassel, Jessica C. |m 129790702:Hassel, Jessica C. |d 910000 |d 911300 |e 910000PH129790702 |e 911300PH129790702 |k 0/910000/ |k 1/910000/911300/ |p 8 | ||
| 999 | |a KXP-PPN1581114109 |e 3025853190 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"June 4, 2012"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"recId":"266889484","disp":"Improved survival with MEK inhibition in BRAF-mutated melanomaThe New England journal of medicine","origin":[{"publisher":"MMS ; MMS","dateIssuedDisp":"1928-","dateIssuedKey":"1928","publisherPlace":"Waltham, Mass. ; Boston, Mass."}],"note":["Gesehen am 04.08.25"],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"subtitle":"NEJM","title":"The New England journal of medicine","title_sort":"New England journal of medicine"}],"corporate":[{"display":"Massachusetts Medical Society","role":"isb"}],"titleAlt":[{"title":"NEJM"}],"pubHistory":["198.1928 -"],"name":{"displayForm":["Massachusetts Medical Society"]},"part":{"year":"2012","volume":"367","pages":"107-114","issue":"2","extent":"8","text":"367(2012), 2, Seite 107-114"},"id":{"zdb":["1468837-2"],"issn":["1533-4406"],"eki":["266889484"]}}],"person":[{"given":"Keith T.","role":"aut","family":"Flaherty","display":"Flaherty, Keith T."},{"display":"Hassel, Jessica C.","family":"Hassel","given":"Jessica C.","role":"aut"},{"family":"Utikal","role":"aut","given":"Jochen","display":"Utikal, Jochen"}],"title":[{"title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","title_sort":"Improved survival with MEK inhibition in BRAF-mutated melanoma"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"note":["Gesehen am 21.08.2019"],"recId":"1581114109","physDesc":[{"extent":"8 S."}],"name":{"displayForm":["Keith T. Flaherty, M.D., Caroline Robert, M.D., Ph.D., Peter Hersey, M.D., Ph.D., Paul Nathan, M.D., Ph.D., Claus Garbe, M.D., Mohammed Milhem, M.B., Lev V. Demidov, M.D., Jessica C. Hassel, M.D., Piotr Rutkowski,M.D., Peter Mohr, M.D., Reinhard Dummer, M.D., Uwe Trefzer, M.D., James M.G. Larkin, M.D., Jochen Utikal, M.D., Brigitte Dreno, M.D., Marta Nyakas, M.D., Mark R. Middleton, Ph.D., Jürgen C. Becker, M.D., Ph.D., Michelle Casey, Ph.D., Laurie J. Sherman, R.N., Frank S. Wu, M.D., Ph.D., Daniele Ouellet, Ph.D., Anne-Marie Martin, Ph.D., Kiran Patel, Ph.D., and Dirk Schadendorf M.D., for the METRIC Study Group*"]},"id":{"doi":["10.1056/NEJMoa1203421"],"eki":["1581114109"]}} | ||
| SRT | |a FLAHERTYKEIMPROVEDSU4201 | ||